Prematurity and congenital malformations differ according to the type of pregestational diabetes.


Journal

BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799

Informations de publication

Date de publication:
02 May 2024
Historique:
received: 11 01 2024
accepted: 30 03 2024
medline: 3 5 2024
pubmed: 3 5 2024
entrez: 2 5 2024
Statut: epublish

Résumé

Diabetes mellitus (DM) is the most common metabolic disorder in pregnancy. Women with Type 2 DM seems to have no better perinatal outcomes than those with Type 1 DM. Single-center prospective cohort observational study. Pregnant women with diabetes (141 with Type 1 DM and 124 with Type 2 DM) that were followed in the university hospital between 2009 and 2021 were included in this study. Clinical data and obstetric and perinatal outcomes were collected. As expected, women with Type 1 DM were younger and had a longer duration of diabetes than women with Type 2 DM. Obesity and chronic hypertension were higher in the group of women with Type 2 DM and their value of HbA1c in the second and third trimesters were lower than in Type 1 DM. No differences in prematurity were found, but more extreme prematurity was observed in Type 2 DM, as well as a higher rate of congenital malformations. The frequency of hypoglycemia and the weight of the newborn was higher in Type 1 DM. The maternal independent factors related to the weight of the newborn were: the glycemic control at the third trimester, the weight gain during pregnancy, and pregestational BMI. Newborns born to mothers with Type 1 DM were larger and had a higher frequency of hypoglycemia, while congenital malformations and precocious preterm was more associated to Type 2 DM. Metabolic control, weight gain and pregestational weight were important determinants of both obstetric and neonatal complications.

Sections du résumé

BACKGROUND BACKGROUND
Diabetes mellitus (DM) is the most common metabolic disorder in pregnancy. Women with Type 2 DM seems to have no better perinatal outcomes than those with Type 1 DM.
METHODS METHODS
Single-center prospective cohort observational study. Pregnant women with diabetes (141 with Type 1 DM and 124 with Type 2 DM) that were followed in the university hospital between 2009 and 2021 were included in this study. Clinical data and obstetric and perinatal outcomes were collected.
RESULTS RESULTS
As expected, women with Type 1 DM were younger and had a longer duration of diabetes than women with Type 2 DM. Obesity and chronic hypertension were higher in the group of women with Type 2 DM and their value of HbA1c in the second and third trimesters were lower than in Type 1 DM. No differences in prematurity were found, but more extreme prematurity was observed in Type 2 DM, as well as a higher rate of congenital malformations. The frequency of hypoglycemia and the weight of the newborn was higher in Type 1 DM. The maternal independent factors related to the weight of the newborn were: the glycemic control at the third trimester, the weight gain during pregnancy, and pregestational BMI.
CONCLUSIONS CONCLUSIONS
Newborns born to mothers with Type 1 DM were larger and had a higher frequency of hypoglycemia, while congenital malformations and precocious preterm was more associated to Type 2 DM. Metabolic control, weight gain and pregestational weight were important determinants of both obstetric and neonatal complications.

Identifiants

pubmed: 38698309
doi: 10.1186/s12884-024-06470-7
pii: 10.1186/s12884-024-06470-7
doi:

Substances chimiques

Glycated Hemoglobin 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

335

Subventions

Organisme : Instituto de Salud Carlos III
ID : PI21/1479

Informations de copyright

© 2024. The Author(s).

Références

Abouzeid M, Versace VL, Janus ED, Davey MA, Philpot B, Oats J, Dunbar JA. A population-based observational study of diabetes during pregnancy in Victoria, Australia, 1999–2008. BMJ Open. 2014;4:e005394.
doi: 10.1136/bmjopen-2014-005394 pubmed: 25398676 pmcid: 4244457
Bardenheier BH, et al. Trends in pre-pregnancy diabetes among deliveries in 19 U.S. states, 2000–2010. Am J Prev Med. 2015;48:154–61.
doi: 10.1016/j.amepre.2014.08.031 pubmed: 25326417
López-De-andrés A, Perez-Farinos N, Hernández-Barrera V, Palomar-Gallego MA, Carabantes-Alarcón D, Zamorano-León JJ et al. A population-based study of diabetes during pregnancy in Spain (2009–2015): Trends in incidence, obstetric interventions, and pregnancy outcomes. J Clin Med. 2020;9(2).
Ornoy A. Effect of maternal diabetes on the embryo, fetus, and children: congenital anomalies, genetic and epigenetic changes and developmental outcomes. Birth Defects Res Part C Embryo Today Rev. 2015;105(1):53–72.
doi: 10.1002/bdrc.21090
Murphy HR, Howgate C, O’Keefe J, Myers J, Morgan M, Coleman MA, et al. Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study. Lancet Diabetes Endocrinol. 2021;9(3):153–64.
doi: 10.1016/S2213-8587(20)30406-X pubmed: 33516295
Balsells M, García-Patterson A, Gich I, Corcoy R. Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis. J Clin Endocrinol Metab. 2009;94(11):4284–91.
doi: 10.1210/jc.2009-1231 pubmed: 19808847
Gaudio M, Dozio N, Feher M, Scavini M, Caretto A, Joy M, et al. Trends in factors affecting pregnancy outcomes among women with type 1 or type 2 diabetes of childbearing age (2004–2017). Front Endocrinol (Lausanne). 2021;11(February):1–9.
Carrasco S, et al. Preconception care in diabetes: predisposing factors and barriers. Endocrinol Diabetes Nutr. 2017;65(3):164–71.
doi: 10.1016/j.endinu.2017.10.014
Guarnotta V, Mineo MI, Giacchetto E, Imbergamo MP, Giordano C. Maternal-foetal complications in pregnancy: a retrospective comparison between type 1 and type 2 diabetes mellitus. BMC Pregnancy Childbirth. 2021;21(1):1–10.
doi: 10.1186/s12884-021-03702-y
GEDE.Grupo Español de Diabetes y. Guía asistencial de diabetes mellitus y embarazo (3a edición). Av Diabetol. 2006;22:73–87. http://www.avancesendiabetologia.org/gestor/upload/revistaAvances/22-1-7.pdf
GEDE. Grupo Español de Diabetes y Embarazo (GEDE). Diabetes mellitus y embarazo Guía De práctica clínica actualizada2020. Prog Obs Ginecol. 2022;65:35–41.
Institute of Medicine (US) and National Research Council (US) Committee. Weight gain during pregnancy: Reexamining the guidelines. http//www.nap.edu/catalog/12584 . 2009;28.
Committee on Obstetric Practice AC of O and G. Weight gain during pregnancy: committee opinion 548. 2013.
Villar. et.al. International standards for newborn weight, length, and head circumference by gestational age and sex: the newborn cross-sectional study of the INTERGROWTH-21st project. Lancet. 2014 [cited 2023 Feb 4];384((9946)):857–68. http://pubmed.ncbi.nlm.nih.gov/25209487/
Stogianni A, Lendahls L, Landin-Olsson M, Thunander M. Obstetric and perinatal outcomes in pregnancies complicated by diabetes, and control pregnancies, in Kronoberg, Sweden. BMC Pregnancy Childbirth. 2019;19(1).
Murphy HR. Improved pregnancyoutcomes in women with type 1 and type 2 diabetes but substantial clinic-to-clinic variations: a prospective nationwide study. Diabetologia. 2017;60:1668–77.
doi: 10.1007/s00125-017-4314-3 pubmed: 28597075 pmcid: 5552835
Schaefer-Graf U. Diabetic pregnancy study group.diabetes in pregnancy: a new decade of challenges ahead. Diabetologia. 2018;61:1012–21.
pubmed: 29356835 pmcid: 6448995
WilsonRD. Preconception folic acid and multivitamin supplementation for the primary and secondary prevention of neural tube defects and other folic acid sensitive congenital anomalies. JOGC. 2015;37(6):534–52.
Wahabi H. Pre-pregnancy care for women with pre-gestational diabetes mellitus: a systematic review and meta-analysis. BMC Public Heal. 2012;17(12):792.
doi: 10.1186/1471-2458-12-792
Melamed N. Perinatal mortality in pregestational diabetes. Int JGynaecol Obs. 2009;104(Suppl 1):S20–4.
Allen AJ. Type-2 diabetes mellitus: does prenatal care affect outcomes? J Matern Neonatal Med. 2017;15:1–5.
Hillman N. Is pregnancy outcome worse in type 2 than in type1 diabetic women. Diabetes Care. 2006;29:2557–8.
doi: 10.2337/dc06-0680 pubmed: 17065703
Søholm JC, Vestgaard M, Ásbjörnsdóttir B, Do NC, Pedersen BW, Storgaard L, et al. Potentially modifiable risk factors of preterm delivery in women with type 1 and type 2 diabetes. Diabetologia. 2021;64(9):1939–48.
doi: 10.1007/s00125-021-05482-8 pubmed: 34146144
Kong L, Nilsson IAK, Gissler M, Lavebratt C. Associations of maternal diabetes and body mass index with offspring birth weight and prematurity. JAMA Pediatr. 2019;173(4):371–8.
doi: 10.1001/jamapediatrics.2018.5541 pubmed: 30801637 pmcid: 6450270
Ladfors L et al. Fetal overgrowth in women with type 1 and type 2 diabetes mellitus. PLoS ONE. 2017;12(11).

Auteurs

Monica Ballesteros (M)

Department of Medicine and Surgery, Rovira i Virgili University, Tarragona, Spain. mballesteros.hj23.ics@gencat.cat.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Carlos III Health Institute, Madrid, Spain. mballesteros.hj23.ics@gencat.cat.
Department of Obstetrics and Gynecology, University Hospital of Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain. mballesteros.hj23.ics@gencat.cat.

A Guarque (A)

Department of Medicine and Surgery, Rovira i Virgili University, Tarragona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Carlos III Health Institute, Madrid, Spain.
Department of Obstetrics and Gynecology, University Hospital of Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.

M Ingles (M)

CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Carlos III Health Institute, Madrid, Spain.
Department of Obstetrics and Gynecology, University Hospital of Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.

N Vilanova (N)

Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.

M Lopez (M)

Department of Medicine and Surgery, Rovira i Virgili University, Tarragona, Spain.
Department of Obstetrics and Gynecology, University Hospital of Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.

L Martin (L)

Department of Medicine and Surgery, Rovira i Virgili University, Tarragona, Spain.
Department of Obstetrics and Gynecology, University Hospital of Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.

M Jane (M)

Department of Medicine and Surgery, Rovira i Virgili University, Tarragona, Spain.
Department of Obstetrics and Gynecology, University Hospital of Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.

L Puerto (L)

Department of Obstetrics and Gynecology, University Hospital of Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.

M Martinez (M)

Department of Obstetrics and Gynecology, University Hospital of Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.

M De la Flor (M)

Department of Medicine and Surgery, Rovira i Virgili University, Tarragona, Spain.
Department of Obstetrics and Gynecology, University Hospital of Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.

J Vendrell (J)

Department of Medicine and Surgery, Rovira i Virgili University, Tarragona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Carlos III Health Institute, Madrid, Spain.
Departament of Endocrinology and Nutrition, Research Unit, University Hospital of Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.

A Megia (A)

Department of Medicine and Surgery, Rovira i Virgili University, Tarragona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Carlos III Health Institute, Madrid, Spain.
Departament of Endocrinology and Nutrition, Research Unit, University Hospital of Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH